Skip to main content

Entereg Disease Interactions

There is 1 disease interaction with Entereg (alvimopan).

Major

Peripheral opioid receptor antagonists (applies to Entereg) intestinal obstruction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Diverticulitis, Peptic Ulcer, Inflammatory Bowel Disease

Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.

References

  1. (2008) "Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories
  2. (2014) "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals
  3. (2017) "Product Information. Symproic (naldemedine)." Shionogi USA Inc

Entereg drug interactions

There are 38 drug interactions with Entereg (alvimopan).

Entereg alcohol/food interactions

There is 1 alcohol/food interaction with Entereg (alvimopan).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer